Factor H is an important regulator of complement activation in plasma and on cell surfaces in both humans and mice. If FH function is compromised, inappropriate complement activation on self-surfaces can have disastrous effects as seen in the kidney diseases atypical haemolytic uremic syndrome (aHUS) and C3 glomerulopathy. As FH constructs have been proposed to be used in treatment for these diseases, we studied the distribution of exogenous FH fragments in mice. Fulllength mFH, mFH1-5 and mFH18-20 fragments were radiolabelled, and their dis- mice. No C3-independent binding to glomeruli was detected. In conclusion, these results show that glomerular glycosaminoglycans and sialic acids alone do not collect FH in kidneys. Deposition of C3 fragments is also needed, which implies that in aHUS, the problem is in simultaneous recognition of C3 fragments and glycosaminoglycans or sialic acids by FH, not just the inability of FH to recognize glomerular endothelium as such.
| INTRODUCTION
Complement is part of the innate immune system and consists of over 30 serum and cell surface proteins. The primary function of complement is to act in the first line defence against invading microbes. However, complement also aids in clearance of cellular and other debris and has adjuvant functions in the adaptive immune response. It is a proteolytic cascade that can be activated via three different pathways: the classical, lectin and alternative pathway. All activation routes lead to cleavage of C3 and activation of the terminal pathway, which leads to membrane attack complex formation. The classical pathway is activated by recognition of surface-bound immunoglobulins with C1q. Recognition of certain microbial surface carbohydrate structures by mannose-binding lectin or ficolins activates the lectin pathway. The alternative pathway has no specific recognition molecules but is continuously activated on surfaces that are not specifically protected. Autologous complement activation is harmful, and several proteins on cell surfaces and serum control complement activation. 1 Factor H (FH) is a central alternative pathway regulator in plasma and plays also a critical role in protecting selfsurfaces from inappropriate complement attack. FH is a single chain glycoprotein that consists of 20 complement control protein domains. The first four domains (FH1-4) are mainly responsible for the regulatory activities, namely the alternative pathway C3 convertase decay accelerating activity and cofactor activity for factor I-mediated cleavage of C3b. 2 Discrimination between self and non-self is based on the ability of FH to bind via its domains FH19-20 to both C3b or C3d and sialic acids or glycosaminoglycans (GAGs). 3, 4 In addition, domains 6-8 are important for GAG binding in certain tissues, for example retina in the eye. 5, 6 The association of FH dysfunction with several diseases emphasizes the key role in complement regulation. Genetic polymorphisms and mutations in FH are found in agerelated macular degeneration, 7, 8 dense deposit disease (DDD) 9 and atypical haemolytic uremic syndrome (aHUS). [10] [11] [12] [13] The two kidney diseases, DDD and aHUS, reveal the vulnerability of the glomerular basement membrane and endothelium to excessive complement activation caused by impaired function of FH. In DDD, mutations or autoantibodies result in the lack of enough functional FH in plasma, which leads to uncontrolled C3 activation in fluid phase, low plasma C3 levels and accumulation of C3 fragments on the glomerular basement membrane (GBM). 9, 14 On the other hand, in aHUS patients, mutations in the domains 19-20 or autoantibodies binding to the same domains lead to complement dysregulation on self-surfaces, most prominently on the glomerular endothelium. [14] [15] [16] [17] [18] [19] Human and mouse FH are both structurally and functionally very similar. 20, 21 Mouse models have provided important information on the role of FH in pathogenesis of diseases and have been used to test some treatment strategies too. FH knockout mice spontaneously develop DDDlike pathology, 22 and an aHUS-like disease develops in mice with FH lacking the C-terminal domains 16-20. 23 Administration of murine or human FH to FH-deficient mice has been shown to reduce glomerular C3 deposition and normalize serum C3 levels. 24, 25 Currently, therapeutic complement C5-inhibitor eculizumab is used in treatment of atypical haemolytic uremic syndrome. 26 The theoretical basis for eculizumab in treatment of aHUS was originally provided by a study on the role of C5 in development of the kidney injury in an aHUS mouse model. 27 FH plays a central role in the pathogenesis of aHUS and DDD. The functional effects of the C-terminal mutations have been studied extensively. These mutations impair the ability to bind sialic acids, glycosaminoglycans and/or C3b/d, [15] [16] [17] [18] thus impairing proper protection of self-
surfaces. It appears that intact binding to both C3b and GAGs or sialic acids is essential for sufficient protection. 28 A recent study highlighted the importance of sialic acid binding and protection of the glomerular endothelium. 29 The aims of this study were to investigate the in vivo distribution of FH in mice and to study if the C-terminal region of FH is responsible for acquisition in certain organs, for example the kidneys, and whether this binding could occur independent of C3b/d-deposition.
| MATERIALS AND METHODS

| Complement proteins and antibodies
Recombinant mFH1-5 and mFH18-20 constructs were produced and purified as previously described. 20 Both constructs contain a carboxy-terminal polyhistidine (his6) tag. The rat monoclonal antibody 10E9 against mouse FH18-20 fragment was produced as previously described. 4 Whole mFH was purified from mouse serum using the monoclonal 10E9 antibody. mice used in the study were C57BL/6 mice. The ages of the mice varied from 3 to 9 months. The general principles of laboratory animal care were carefully followed in the experiments, and all the experiments were approved by the Ethical Committee of Animal Experiments, the University of Helsinki (permissions #138/02 and #180/03).
| In vivo injections
Three different 125 I-labelled proteins, mFH purified from mouse serum, recombinant mFH18-20 or mFH1-5, were injected either in WT mice, FH À/À mice or the FH
mice. The iodination of the proteins was carried out with the Iodogen method, 31 and PD-10 columns were used to separate proteinbound activity from free 125 I. Approximately 24 h before the injections, the mice were given drinking water containing 100 lg/mL of potassium iodide to block accumulation of possible free 125 I in the thyroid gland and stomach. The drinking water iodide was not given to the mice used for the in vivo scintigraphy, as the thyroid gland was utilized as an anchor point for interpretation of the results. The 125 I-labelled proteins were injected into the tail vein in a total of 100 lL of PBS (for the in vivo scintigraphy) or intraperitoneally in a total of 250 lL of PBS (for the organ distribution or in situ autoradiography).
| Scintigraphy
After intravenous administration of 6-20 lCi of 125 I-labelled proteins (specific activities of 0.5-5 9 10 7 cpm/lg), the mice were anesthetized with pentobarbital and imaged at two time points. The images were detected from the ventral (anteriorposterior) view from each mouse at 4 and 24 h, and counts were collected for 30 min per image. Imaging was performed with a low energy high-resolution collimator on 30 keV c-energy peaks (35% window) with Picker Prism 1500 XP c -camera (Picker International, Highland Heights, OH, USA) utilizing Odyssey software. A matrix size of 512 9 512 9 16 was used for imaging, making the pixel size on the images 0.44 9 0.44 mm.
| Distribution to organs
Organ distribution was studied by measuring radioactivity in each organ separately. After 4 or 24 h of intraperitoneal injection of the 125 I-labelled proteins, the mice were sacrificed and different organs, blood and urine were collected. Each organ was weighed, and the level of radioactivity was measured using either the 1470 or 1480 WIZARD gamma counter (Wallac, Turku, Finland).
| Autoradiography of kidney cryosections
To examine the histological distribution of mFH or its recombinant fragments in vivo, 125 I-labelled proteins (3-5 9 10 8 cpm, specific activity of 2-5 9 10 7 cpm/lg) were injected intraperitoneally in WT and FH
mice. The animals were sacrificed at 4 or 24 h. Cryosections of kidneys were prepared on Superfrost TM Ultra Plus objective slides (Menzel, Braunschweig, Germany) and used for autoradiography using a method modified from visualization of in situ hybridizations. Briefly, the frozen slides were thawed and immediately subjected to rinsing in increasing alcohol solutions (5-100% ethanol) followed by air drying. Then, the slides were submerged in Kodak NTB2 nuclear emulsion diluted 1:1 with water at 42°C in full darkness. The emulsified slides were dried, exposed for 1-5 days and developed using Kodak D-19 developer, fixed and stained with haematoxylin. The slides were examined using dark-field optics in Olympus BX51 microscope (Olympus, Tokyo, Japan) and original magnifications used were 49 and 209. Images were taken with Olympus DP70 digital camera (Olympus).
| Immunofluorescence
For immunofluorescence microscopy studies, cryosections (4 lm) of FH
À/À mice kidneys were prepared on SuperFrost TM Ultra Plus objective glass slides (Menzel).
The samples were fixed with acetone. About 1% BSA in PBS was used to block non-specific binding. The samples were first incubated for 30 min with 10 lg/mL of recombinant mFH18-20 at room temperature. After washing, the samples were incubated with 20 lg/mL of monoclonal rat anti-mouse antibody 10E9, polyclonal goat anti-rat megalin antibody P-20, or both for 30 min at room temperature. AlexaFluor488 â -labelled donkey anti-rat IgG and AlexaFluor546 â -labelled donkey anti-goat IgG were used at 1:200 dilution for detection. After a 30 min incubation at room temperature, the slides were washed, dried and mounted in Immu-Mount TM mounting medium (Fisher Scientific, Pittsburgh, PA, US). The sections were then examined with Olympus BX51 microscope with the appropriate fluorescent filters (Olympus). The original magnification used was 209. Images were taken with Olympus DP70 digital camera (Olympus). 
| Distribution at the organ level
After whole body imaging, the distribution of FH and the fragments at the organ level was studied. First WT and FH À/À C3 À/À mice were studied in detail as the differences between the mice types were not evident based on the scintigraphy results and we aimed to evaluate C3b-independent binding of FH. The 24 h time point was used as we wanted to investigate the more stable interactions between mFH and the tissues. Most of the full-length mFH remained in the circulation as indicated by the highest radioactivity in the blood (Figure 2A) . In WT mice, the mFH1-5 fragment was detected only in solid organs (Figure 2B) , and with mFH18-20, only minimal radioactivity was detected in the blood in both WT and FH À/À C3 À/À mice ( Figure 2C ). None of the proteins passed the bloodbrain barrier as the brain did not show any radioactivity (Figure 2 ). Full-length mFH did not show specific accumulation to kidneys (Figure 2A) . Interestingly, both mFH-15 and mFH18-20 accumulated in the kidneys ( Figure 2B ,C). Radioactivity in stomach was relatively high with all the proteins, which could be mostly due to accumulation of free 125 I (Figure 2 ).
| mFH fragments are secreted in urine
Radioactivity between blood, solid tissues and urine was compared to determine if most of the 125 I-labelled mFH fragments were bound to tissues or secreted in urine. The highest activity was detected in the urine already at 4 h, indicating that substantial amounts of the protein fragments are rapidly excreted via the kidneys (Figure 3 ).
| Both of the mFH fragments accumulate in the kidneys
The distribution of the mFH fragments in WT, FH À/À and FH À/À C3 À/À mice kidneys compared with selected organs was investigated to evaluate the effect of C3 deposits on FH binding to kidneys and other organs (Figure 4 ). Both the 4 h and 24 h time points were used, as accumulation in the kidneys was seen with WT and FH À/À C3 À/À mice at 24 h but also because the protein fragments were also excreted in Figure 4A ), which could reflect excretion of the protein in urine. At 24 h, the activity in the kidneys was already decreasing ( Figure 4B ). Accumulation of the mFH18-20 fragment in the kidneys was slower than the mFH1-5 fragment. At 4 h, the activity in the different organs was at the same level ( Figure 4C ), but at 24 h, the activity in the kidney was higher compared to the other organs with the mFH18-20 fragment ( Figure 4D ).
| FH is not acquired on glomeruli independent of C3 fragments
As accumulation in the kidneys was seen with the mFH fragments (Figure 4) , we decided to localize the binding at the tissue level. As this accumulation was seen in all types of mice without marked differences and because we were interested in C3b-independent binding, only WT and FH 
| DISCUSSION
Complement FH abnormalities play a central role in the development of aHUS and DDD. Based on studies in mouse models, full-length FH and protein constructs with FH fragments have been proposed as treatments for these conditions. 24, 32, 33 However, only scarce information on the distribution of exogenous FH in mice is available. We investigated the in vivo distribution of exogenous mFH in mice. Examination at the organ level in WT mice showed that most of the full-length FH remains unbound in circulation and that both of the mFH fragments accumulated in the kidneys. Recruitment of the mFH fragments to kidneys seemed to be independent of C3 as clear differences between WT, FH À/À or FH been proposed that some of these glycans could act as specific recognition molecules for the FH C-terminus in the kidney. 29 As the glomerular endothelium is susceptible to complement mediated damage and is dependent on protection by FH, it might be appropriate for FH to be present at the glomeruli already before complement attack and generation of C3b deposition. In our experiments, C3b-independent glomerular binding of full-length FH or the C-terminal fragment was not detected in vivo or in vitro. Interaction with sialic acids or glycosaminoglycans alone (in the absence of C3b or C3d depositions) does not seem to be strong enough to keep FH in place, although these glycans are essential for efficient FH binding to self-surfaces. 34 It is theoretically possible that the binding of recombinant mFH18-20 to glomerular cell surfaces was affected by the C-terminal polyhistidine tag or deglycosylation treatment. We consider this unlikely since in previous in vitro studies, the his-tagged FH fragments and antibody-purified plasma-derived whole mFH displayed good binding to the ligands. 4 Another recent study has shown that full-length FH and a mini-FH molecule containing the FH18-20 fragment bind to the glomerulus when injected into FH À/À mice with glomerular C3 depositions. 33 This and our results together imply that FH is not preventively recruited to the glomerulus but appears when C3 fragments are also present and protection from excessive complement activation is needed. Intact binding to both sialic acids or GAGs and C3b is required for sufficient protection of the glomeruli and other self-surfaces. If either of these functions is compromised and FH does not recognize the GAG-C3b or sialic acid-C3b complex, complement attack can have serious consequences as shown by FH mutations in aHUS. 16, 35 The glomerular endothelium likely encounters constant low-grade complement challenge by covalent deposition of some C3b molecules. These C3b deposits are, however, likely to be degraded rapidly by factor I in the presence of either FH or another cofactor. In humans, FH can be found in normal kidneys in small amounts. 36 We did not observe ) and B (WT), the general dark-field images of the kidney sections are shown in low power magnification (49 objective) to demonstrate higher amount of radioactivity-exposed emulsion in cortex compared with medulla. In panels C (FH 
C3
À/À mice.
Although leaking of the mFH18-20 through the glomerular filtration barrier was somewhat unexpected, it was not surprising that the mFH18-20 bound to tubular epithelium. Previous studies have shown FH binding to heparan sulphate on proximal tubular epithelial cells in both humans and mice and that FH protects epithelial cells from autologous complement activation in mice. [37] [38] [39] The binding sites within the FH19-20 fragment are known to mediate this interaction. Normally, only small amounts of complement proteins are present in the urinary space. In proteinuria conditions, where the glomerular filtration barrier is damaged and leaks proteins into the urinary space, complement activation is known to mediate the development of further interstitial damage, while complement inhibition has beneficial effects. 40 In ischaemia-reperfusion (I/R) injury, tubular injury is mainly mediated by alternative pathway activation, and therefore, FH binding to proximal tubular epithelial cells might attenuate the damage. 41, 42 This is likely to happen as targeted AP inhibition with the CR2-FH hybrid molecule containing the complement regulatory domains FH1-4 has been shown to reduce the tubular damage in a mouse model of I/R-injury. 42 In conclusion, we provide new information on the distribution of exogenous mFH and mFH fragments in vivo and show that FH does not bind in detectable amounts to glomeruli independent of C3 fragments. Glomerular protection by FH thus relies on the ability of FH to recognize C3b in complex with sialic acid or GAG, a phenomenon which seems to be compromised by aHUS-associated FH mutations.
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